VRCA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the Firm

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

VRCA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the Firm

PR Newswire

NEW YORK, July 2, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ: VRCA). Investors who purchased Verrica securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/vrca.       

The investigation concerns whether Verrica and certain of its officers and/or directors have violated federal securities laws.

On June 29, 2020, Verrica announced that it received a letter from the U.S. Food and Drug Administration ("FDA") as part of the FDA's ongoing review of the Company's New Drug Application for VP-102 (cantharidin 0.7% topical solution), Verrica's lead product candidate for the treatment of molluscum contagiosum.  According to the Company, the letter cited deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.  While Verrica stated that the letter did not specify any particular items, it noted that the FDA's periodic requests for additional information pertained to chemistry, manufacturing and control aspects of the drug-device combination.  The Company also stated that its ability to address the requests had been "significantly impacted" by COVID-19 disruptions.  Following this announcement, Verrica's stock price fell $3.06 per share, or 21.75%, to close at $11.01 per share on June 30, 2020.

If you are aware of any facts relating to this investigation, or purchased Verrica shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/vrca.  You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein | Yael Hurwitz
212-697-6484 | [email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vrca-investor-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-verrica-pharmaceuticals-inc-and-encourages-investors-to-contact-the-firm-301087437.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

Copyright CNW Group 2020

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).